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IntroductIon
The main drawback of current immunosuppressive therapies 
is their pleiotropic side-effects due to the ubiquitous distribu-
tion and involvement in multiple functions of their molecular 
targets. A plausible alternative seems to be the Jak fam-
ily of cytoplasmatic protein kinases (Jak1, Jak2, Jak3, and 
Tyk2) that associate with type I and type II cytokine recep-
tors. Among them, two essential characteristics make Jak3 
particularly appealing: (i) Jak3 is predominantly expressed in 
hematopoietic linage, while Jak1, Jak2, and Tyk2 are ubiqui-
tously expressed, and (ii) Jak3 specifically binds the γ com-
mon subunit (γc) cytokine receptor and it is uniquely activated 
by γc family cytokines [interleukin-2 (IL-2), IL-4, IL-7, IL-9, 
IL-15, IL-21], unlike the other family members which bind 
multiple cytokine receptors.1–3
The importance of Jak3 in lymphoid system development 
is highlighted in gene targeted mice and in humans with pri-
mary immunodeficiency: Jak3 knockout mice and Jak3-SCID 
human patients suffer from a profound immunodeficiency.4–6 
Furthermore, increased Jak3 expression has been associ-
ated with immune system disorders such as rheumatoid 
arthritis in animal models and human patients.7–9
Jak inhibitors currently under clinical development have 
demonstrated efficacy in the treatment of rheumatoid arthritis, 
allograft rejection and psoriasis.10–12 Nevertheless safety con-
cerns arise from their lack of selectivity versus other kinases13 
and Jak family members.14,15 A pan-Jak inhibition could lead 
to undesirable side-effects because of the roles of Jak1 in 
innate immunity Jak2 in erythropoiesis: systemic inhibition of 
Jak1 would lead to increased susceptibility to viral and bacte-
rial pathogens, whereas Jak2 systemic inhibition would lead to 
anemia, thrombocytopenia, and leukopenia.16,17 Indeed, clini-
cal studies have revealed increased incidence of infections, 
mild reduction in hemoglobin levels and neutropenia most 
likely due to the pan-Jak activity of inhibitors tested.11,12,18
All γc cytokines exert their effect through the Jak1-Jak3 tan-
dem, whose relative contribution to the signaling pathway is 
not fully understood. In this regard, whether a putative selective 
Jak3 inhibition would disrupt γc cytokine signaling and, if so, 
would it afford immunosuppressive activity, remains controver-
sial. On the one hand, a virtually Jak3-selective compound has 
reported efficacy in mouse and rat arthritis models.9,19 How-
ever, the scope of the results obtained with small molecules 
is limited by their unavoidable lack of selectivity. On the other 
hand, data from reconstituted systems in vitro has suggested 
that Jak1 plays a dominant role in the γc cytokine signal trans-
duction.20 Nevertheless, the consequences of an acute-spe-
cific intervention on endogenous Jak over γc cytokine signaling 
and T cell activation have not been investigated to date.
Here, we sought to discriminate the direct implications of 
individual Jak enzymes involved in γc cytokine (i.e., IL-2) sig-
naling and T cell activation, as well as the immunosuppressive 
potential of Jak3 downregulation in vivo. We have used RNA 
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interference (RNAi) technology to knockdown Jak1 and Jak3 
in primary T lymphocytes in vitro and studied the responsive-
ness of these cells to several activation stimuli. Furthermore, 
we have tested whether silencing of Jak3 in T cells would 
provide an anti-inflammatory benefit in vivo.
The main challenge of RNAi applications is its successful 
delivery into the cytoplasm of target tissues or cells,21 which 
is particularly convoluted in lymphoid lineage.22 Furthermore, 
RNAi machinery itself works inefficiently in T lymphocytes, as 
compared with other cell types.23 Due to the aforementioned 
problems with small interference RNA (siRNA) delivery and 
functionality, studies involving target silencing in primary 
T lymphocytes have been seldom reported.
In the present study, we have used synthetic, chemically 
modified siRNA sequences to successfully transduce human 
and murine T lymphocytes without associated toxicity. We 
have demonstrated that specific Jak3 knockdown in primary 
T lymphocytes is sufficient to impair not only the Jak-Stat 
pathway, but also TCR activation and its downstream conse-
quences. Most importantly, Jak3 knockdown in Th1-polarized 
effector cells prevented delayed type hypersensibility (DTH) 
reaction in vivo, highlighting the importance of Jak3 in Th1-
driven inflammatory process. Furthermore, a dual Jak1–
Jak3 intervention did not contribute to a deeper effect over 
the described phenotype. Altogether, the data presented in 
this manuscript supports the advisability of Jak3-selective 
inhibition as immunomodulatory strategy in pathologies with 
a strong Th1 component, such as rheumatoid arthritis.
reSuLtS
sirnA delivery and target silencing in human primary 
t lymphocytes
To overcome the difficulties associated with lymphoid cell 
transfection, we have used the synthetic, chemically modified 
ACCELL siRNA sequences that allow for a vector-free passive 
transfection. Our experimental conditions reported an exception-
ally efficient (90 ± 5%, n = 4) and homogeneous siRNA uptake 
in primary human T lymphocytes (Figure 1a). Confocal analysis 
confirmed efficient internalization and cytoplasmic localization 
of the siRNA sequences, as indicated by green fluorescence 
localization (corresponding to FAM-Scr-siRNA) between plas-
matic membrane (red) and nuclei (blue) markers (Figure 1b).
Next, knockdown efficiency against Jak1 and Jak3 in pri-
mary human T lymphocytes was tested. Dose response 
experiments were performed with Jak1 and Jak3 siRNA 
sequences and we established 1 µmol/l as the dose report-
ing maximal silencing with no toxicity (data not shown). Under 
these conditions, a consistent and stable target mRNA knock-
down was observed up to 10 days after transfection. JAK1 
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Figure 1 efficient small interference rnA (sirnA)  transfection 
and target gene knockdown in human primary t lymphocytes. 
(a) Primary human T lymphocytes were incubated with 1 µmol/l 
Scrambled siRNA fluorescently labeled with FAM (FAM-Scr-siR-
NA) for 3 days. Fluorescence incorporation in Mock (empty histo-
gram) and FAM-Scr-siRNA transfected T cells (green histogram) 
was assessed by flow cytometry. A representative histogram of four 
independent experiments is shown. (b) Cytoplasmatic localization 
of FAM-Scr-siRNA (green) sequence was confirmed by confocal 
microscopy. Cy3-CD3 (red) mAb was used as membrane marker. 
Nuclei were labeled with DRAQ5 (blue). A representative view of 
three independent experiments is shown. (c) JAK1 and (d) JAK3 
mRNA content at day 3 (d3) and 7 (d7) post-transfection with 1 
µmol/l indicated siRNA sequence was assessed by quantitative re-
verse transcription-PCR (RT-PCR). GUSb was used as housekeep-
ing gene. Results are expressed as mean ± SEM relative to Mock; 
n = 3; &P < 0.001 versus Scr. (e) Western blot from protein extracts 
obtained on d3. A representative blot is shown. (f) Blots were quan-
tified by subsequent densitometry. Results are expressed as mean 
± SEM; n = 6–10; *P < 0.05; #P < 0.01; &P < 0.001 versus Scr. 
Two sequences (described in Materials and Methods section) were 
tested for each target, which performed equally (data not shown). 
Results are expressed as the mean values of the two sequences.
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mRNA was reduced to 43 ± 3% and 51 ± 0% on day 3 and 
7 post-transfection respectively, as compared to the control 
Mock group (Figure 1c,d). These results demonstrate good 
specificity, functionality and stability of silencing provided by 
ACELL siRNA sequences. Accordingly, a sequence-specific 
knockdown was noteworthy at the protein level by western blot 
(Figure 1e). Densitometry revealed a 30 ± 6% and 22 ± 4% 
Jak1 and Jak3 residual protein content, respectively (Figure 
1f). Surprisingly, Jak1 mRNA and protein content was slightly 
increased in response to Jak3 knockdown (Figure 1c,e,f).
Jak3 is essential for the IL-2-mediated Jak-Stat signaling 
pathway
To elucidate whether an acute Jak3 knockdown is sufficient 
to impair the γc cytokine-mediated Jak-Stat pathway (repre-
sented in Figure 2a), the steady-state phosphorylation status 
of Jak1, Jak3, and Stat5a/b was analyzed. A high (1,000 
nmol/l; Figure 2b,c) and mild (250 nmol/l; Figure 2b,d) 
siRNA concentration treatments were tested to ascertain the 
trend in phosphorylation ratios. We found that Jak1 knock-
down was accompanied by a concomitant reduction of 
phospho-Jak1, whereas phospho-Jak3 was not significantly 
decreased, resulting in sustained phospho-Jak1 versus total 
Jak1 and phospho-Jak3 versus total Jak3 ratio. Conversely, 
after Jak3 silencing, both Jak3 and Jak1 phosphorylated 
forms dropped. When normalized by total amount of Jak3 
protein, it was evidenced that Jak3 knockdown markedly 
repressed Jak1 phosphorylation, while residual Jak3 became 
highly phosphorylated, resulting in a significant reduction of 
the P-Jak1/Jak1 ratio and a striking increase in P-Jak3/Jak3 
ratio (Figure 2b,c,d). Taken together, these results suggest 
that Jak3 phosphorylation is a first step in the IL-2-induced 
trans-phosphorylation cascade. Furthermore, Stat5a/b phos-
phorylation was impaired after either Jak1 or Jak3 knockdown 
(Figure 2e). Jak3 silencing almost completely prevented IL-2-
-induced Stat5a/b phosphorylation; while in Jak1 silenced 
cells a remainder Stat5a/b phosphorylation over basal levels 
(Ct) was evident, suggestive of a prominent role of Jak3 in 
IL-2 signal transduction. Additionally, Jak1-Jak3 cosilenc-
ing did not potentiate the effect of Jak3 silencing in terms 
of Stat5a/b phosphorylation. Equivalent results regarding 
Jak and Stat5a/b phosphorylation were obtained with partial 
Jaks silencing (circa 50%) achieved after 250 nmol/l siRNA 
treatments (data not shown). These results indicate that both 
kinases are necessary for effective IL-2 signal transduction 
and there is not an additive effect in the cytokine signaling 
after dual Jak1 and Jak3 intervention.
As a result of Jak-Stat pathway blockade, expression of the 
downstream target genes suppressor of cytokine signaling 3 
(SOCS3) (Figure 2f) and B-cell leukemia/lymphoma 2 (BCL2) 
(Figure 2g) were similarly reduced close to basal levels (no 
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Figure 2 Single Jak depletion compromises the Jak-Stat sig-
naling pathway. Human primary T lymphocytes were cultured 
in the absence (Ct) or presence of interleukin-2 (IL-2) stimulus 
during either Mock, Scrambled (Scr), Jak3, Jak1, or Jak1+Jak3 
small interference RNA (siRNA) treatments at 1 µmol/l or 
250 nmol/l.  After 3 days, IL-2 signal transduction was evaluated. 
(a) Scheme of γc cytokine-mediated Jak-Stat pathway. (b) Jak1-P 
Tyr1022–1023 and Jak3-P Tyr980–981 were analyzed by western blot. Rep-
resentative blot of six independent experiments is shown. (c) Den-
sitometric analysis of blots obtained from cells treated with 1 µmol/l 
siRNA; (n = 6). (d) Densitometric analysis of blots obtained from 
cells treated with 250 nmol/l siRNA; (n = 4). Data are expressed 
as phospho-Jak/total Jak ratio relative to Mock treatment. (e) 
Stat5a/b phosphorylation was analyzed using the Luminex xMAP 
technology (n = 4). Data are expressed as phospho-Stat5a/b rela-
tive to nonstimulated control treatment (Ct). In addition, the expres-
sion of downstream targets genes as (f) suppressor of cytokine 
signaling 3 (SOCS3) (n = 4) and (g) B-cell leukemia/lymphoma 
2 (BCL2) (n = 4) was examined. Gene expression was quantified 
by  quantitative reverse transcription-PCR (RT-PCR). As housekeep-
ing gene β-glucoronidase (GUSb) was used. Each value represents 
the mean relative amount of mRNA with respect to Mock treatment. 
(h) IL-2 induced interferon-γ (IFNγ) secretion was evaluated as IFNγ 
on the culture supernatant determined by enzyme-linked immu-
nosorbent assay (ELISA) (n = 4). Data are expressed as mean ± 
SEM; *P < 0.05; #P < 0.01; &P < 0.001 versus Scr; §P < 0.05 versus 
Jak3 siRNA.
Molecular Therapy–Nucleic Acids
Testing the Potential Immunosuppressive Efficacy of Specific Jak3 Inhibition 
Gómez-Valadés et al
4
no additive effect upon dual silencing. Accordingly, an end 
point product of the pathway, namely IL-2-induced interferon-γ 
(IFNγ) secretion, was reduced to a 47 ± 6% and 41 ± 11% 
after Jak3 and Jak1 silencing, respectively (Figure 2h), con-
firming that a single Jak knockdown is enough to disrupt the 
Jak-Stat pathway.
To further evaluate the functional significance of Jak1 and/
or Jak3 knockdown, cell viability was assessed on day three 
(d3) and day seven (d7) after transfection as an indicator of 
IL-2-dependent T-cell proliferation. As expected, in absence 
of IL-2 stimulus (Ct) there was no increment in cell viability 
at d7 versus d3. We found no signs of altered cell viability 
between different treatments on d3, whereas on d7 a strik-
ing increment in viable cell number was evident in control 
groups (Mock and Scr), indicative of IL-2-induced cell pro-
liferation. Conversely, on d7 cell viability was stagnated or 
even declined in Jak3 and/or Jak1 siRNA-treated groups, 
suggesting a blockade of IL-2-induced cell proliferation and/
or cell death induction (Figure 3a).It is remarkable that, 
albeit equivalent target knockdown efficiency, Jak3 silenc-
ing had a deeper impact in proliferation than Jak1 silencing. 
Furthermore, we did not observe any additive effect over 
cell viability after dual compared with single Jak3 silenc-
ing, but we did so when comparing dual versus single Jak1 
silencing. To test whether the role of Jak1 in IL-2 signal-
ing could be emphasized with a mild Jak3 inhibition, dose-
response siRNA treatment was performed to obtain partial 
Jak knockdown (Figure 3b). No additive effect over cell 
viability was found at any dose tested (Figure 3c), support-
ing the idea that Jak3 plays a prominent role in IL-2-induced 
cell proliferation.
In order to dissect the mechanism responsible for the 
decreased cell viability, apoptosis was measured by flow 
cytometry. In agreement with viability data, siRNA treatments 
did not induce cell death or apoptosis on d3 (data not shown), 
whereas on d7 we did observe apoptosis and cell death 
induction in Jak1 and/or Jak3 siRNA-treated cells (Figure 
3d). Accordingly, reduced expression of the anti-apoptotic 
gene BCL2 was found in these groups (Figure 2e). Interest-
ingly, Jak3 knockdown resulted in higher cell death and apop-
tosis induction compared with Jak1 knockdown, while dual 
intervention resembled Jak3 knockdown phenotype.
Altogether, these results indicate that both enzymes are 
required for a complete γc cytokine signal transduction in 
T cells and that a single intervention is sufficient to impair 
downstream effects like IFNγ secretion and cell proliferation, 











































































































































Figure 3 Jak3 and Jak1 are essential to maintain cell viability 
in interleukin-2 (IL-2) activated t lymphocytes. Human primary 
T lymphocytes were cultured in absence (Ct) or presence of IL-2 
stimulus during either Mock or 1 µmol/l Scrambled (Scr), Jak3, 
Jak1, or Jak1+Jak3 small interference RNA (siRNA) treatments. 
(a) Cell viability was measured on day three (d3) and seven (d7) 
after siRNA incubation. Data are represented as mean ± SEM % 
viability versus control Mock group on d3. n = 8; *P < 0.05 and 
&P < 0.001. (b) Dose-response silencing in primary human T lym-
phocytes. Cells were treated with 500, 250, and 100 nmol/l indi-
cated siRNA sequences. On d3 protein extracts were obtained and 
analyzed by western blot. A representative blot from at least three 
independent experiments is shown. (c) Cell viability was measured 
on d7 after 1,000 nmol/l (n = 8), 500 nmol/l (n = 5), 250 nmol/l (n 
= 8), or 100 nmol/l (n = 7) indicated siRNA sequences treatment. 
Data are expressed as mean ± SEM relative to control Mock group 
on d3. (d) Dead and/or apoptotic cell population secondary to Jak 
knockdown was assessed on d7 by cytometry using Alexa Flu-
or488-Annexin V and propidium iodide (PI) double staining. Death 
(AnnV+/PI+) and apoptotic (Annexin V+/PI) populations were quan-
tified. As positive control for apoptotic stimulus (Ct+), cells were 
incubated with 1.5 µmol/l camptothecin for 24 hours. Data are ex-
pressed as mean ± SEM relative to Mock control group. n = 4; *P < 
0.05; #P < 0.01; &P < 0.001 versus Scr.
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Jak3 and Jak1 are involved in early tcr activation
To understand further the impact of Jak3 knockdown in lym-
phocyte activation, the putative relationship between Jak3 
and TCR, whose interaction is controversial,24–26 was ana-
lyzed. Jak3, as well as Jak1 and dual knockdown impaired 
early TCR signaling, as indicated by a slightly reduced phos-
phorylation of CD3ε-chain and CREB after CD3-CD28 mAb 
challenge (Figure 4a, b). Furthermore, homotypical cell 
clustering and proliferation, ultimate phenotypical hallmarks 
of TCR activation, were accordingly altered: CD3-CD28 mAb-
activated T cells exhibited prominent cell clusters, while sin-
gle Jak3, Jak1, or dual siRNA treatments almost completely 
prevented clustering (data not shown) and diminished cell 
proliferation (Figure 4c).
Overall, these results suggest that not only Jak3, but 
also Jak1 play a dual role in the integration of TCR and γc 
cytokine-mediated T cell activation. These results prompted 
us to further investigate whether Jak3 intervention could be 
used to interfere with T cell activation and antigen-driven 
inflammation in vivo.
sirnA delivery and Jak silencing in murine t cells
The ex vivo transfection of murine Th1 effector cells with 
ACCELL siRNA sequences was optimized in order to obtain 
Jak-silenced Th1 cells to be used later in our adoptive cell 
transfer model (described in Materials and Methods section). 
We established optimal transfection conditions that report 
good cellular viability (73 ± 3%, n = 4, measured as FSC-
Height-SSC-Height, data not shown) and optimal transfection 
rates (98 ± 1%, n = 4). An heterogeneous siRNA uptake and 
cytoplasmatic localization was evidenced by the double-peak 
histogram (Figure 5a) and confocal images (Figure 5b). 
Interestingly, as seen in confocal sections, the low-range flu-
orescence peak corresponds to a CD3+ population. This may 
be due to the lower rates of siRNA uptake characteristic of 
murine T lymphocytes, as compared with the other cell types 
(i.e., dendritic cells (DC) and macrophages) present in the 
splenocyte:lymph node suspension.
Furthermore, a satisfactory silencing efficiency was 
obtained. After sequence-specific siRNA treatment against 
mouse Jak1 (mJak1 siRNA) and mouse Jak3 (mJak3 siRNA), 
Th1 cytokine-induced increase in jak1 and jak3 mRNA levels 
was attenuated close to the baseline, non-Th1-stimulated con-
ditions (Th1-). As compared to nontargeting siRNA treatment 
(Scr), jak1 (Figure 5c) and jak3 (Figure 5d) mRNAs were 
reduced in a 42 ± 6% and 49 ± 1% (n = 5), respectively.
Specific Jak3 targeting prevents th1-mediated 
 inflammation in vivo
Rheumatoid arthritis is an inflammatory disorder with a 
strong Th1 component. To test the potency of selective 
Jak3 downregulation in preventing inflammatory process 
in vivo we used a DTH model elicited by ex vivo-generated 
OVA
323–339-activated Th1 effector cells from DO11.10 TCR 
transgenic mice (OVA-TCRtg Th1 cells). After adoptive trans-
fer of OVA-TCRtg Th1 cells into naive wild type recipient, a 
single OVA323–339 challenge induce a traceable local inflam-
mation with a strong Th1 component which is mediated by 
the transferred cells.27–29
Transfection of the OVA-TCRtg Th1 cells with mJak1 and 
mJak3 siRNA sequences resulted in a 59 ± 2% and 48 ± 
2% (n = 4, P < 0.01) jak1 and jak3 sequence specific mRNA 
drop, respectively, as compared to control, nontargeting 
siRNA transfected cells (Scr). In correlation, densitometric 
analysis of western blots revealed a Jak1 and Jak3 protein 
content fall to 58 ± 8% (n = 5, P < 0.01) and 50 ± 4% (n = 5, 
P < 0.01), respectively (data not shown).
Consistently with Th1 inflammatory processes, OVA323–339 
challenge elicited a dramatic IFNγ  rise in mice adoptively 



























































































































































Figure 4 Jak1 and Jak3 targeting equally impairs early t cell receptor (tcr) signaling events and cell activation in vitro. On 
day 3 after either Mock (empty bars) or 1 µmol/l Scrambled (dotted bars), Jak3 (black bars), Jak1 (light gray bars), or Jak3 +Jak1 (dark 
gray bars) small interference RNA (siRNA) treatments, human T lymphocytes were stimulated with CD3-CD28 mAb for 10 minutes. 
(a) Phospho-CD3ε and (b) phospho-CREB were detected using the Luminex xMAP system. Data are expressed as mean ± SEM relative 
phosphorylation versus non-CD3-CD28-stimulated control (Ct). n = 4, *P < 0.05; #P < 0.01 versus Scr. (c) Cellular viability was assessed 
before and 72 hours after CD3-CD28 challenge. Data are expressed as mean ± SEM relative to control Mock group before stimulus. n = 3, 
*P < 0.05; #P < 0.01; &P < 0.001 versus Scr.
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but not in nonadoptively transferred mice (Ct). As expected, 
IL-4 levels remained unaltered (data not shown). Concomitant 
with plasmatic IFNγ levels, swelling was evident in OVA323 339 
challenged footpad from Mock- and ScrsiRNA-treated groups. 
Importantly, Jak3 knockdown rendered resistance to antigen-
triggered plasmatic IFNγ  rise (Figure 6a) and showed a 
substantially reduced footpad swelling (Figure 6b). It is note-
worthy to point out that dual mJak3-mJak1 siRNA treatments 
did not provide any additional anti-inflammatory effect, as 
compared to single Jak3 silencing (Figure 6a,b).
DTH reaction is characterized by a strong cellular infil-
trate. Microscopic analysis of the footpads correlated with 
inflammation severity. In line with cytokine profile and footpad 
swelling, substantial inflammatory cell migration into subcu-
taneous adipose and muscular tissue was observed in foot-
pads of Mock and Scr-treated mice in response to OVA323–339 
challenge (Figure 6c; panels (i) and (ii)). In contrast, overall 
inflammatory infiltration and tissue damage at the antigen-
challenged site was significantly ameliorated in the mJak3 
knocked-down group, with only mild subcutaneous infiltrate, 
or even complete absence of inflammation (Figure 6c; panel 
(iii) and (iv)). Inflammatory histological scores of evaluated 
sections are shown in Figure 6d. These data, in conjunc-
tion with macroscopic observations and plasmatic cytokine 
profile, strongly advocate a crucial role of Jak3 in Th1 inflam-
matory response.
To further analyze antigen-specific response at a cellular 
level, draining lymph nodes were isolated and restimulated in 
vitro with OVA323–339. As expected, lymphoid cells from naive 
mice (Ct, not adoptively transferred with Th1 effector cells) 
did not responded to in vitro OVA323–339 exposure in terms 
of proliferation and IFNγ secretion (Figure 6e,f). Cells from 
mice that had been adoptively transferred with control OVA-
TCRtg Th1 cells (Mock and ScrsiRNA-treated) were capable 
of proliferating and secreting IFNγ after in vitro OVA323–339 re-
challenge. In contrast, Jak-silenced groups poorly proliferated 
and secreted lower IFNγ levels, similarly to lymphoid cells 
from naive, nonadoptively transferred mice (Figure 6e,f). 
Together, these data suggest that T cells are unresponsive to 
antigen activation in the absence of Jak3 activity.
Overall, our results strongly reinforce the concept that 
Jak3-specific intervention could provide therapeutic benefits 
in immunomodulatory therapies and that dual Jak1-Jak3 
intervention would not account for a synergistic effect in Th1-
mediated inflammatory disorders.
dIScuSSIon
Herein, we describe reliable and selective Jak3 knockdown in 
lymphocytes using RNAi technology and investigate its direct 
implications in IL-2-mediated signaling and T cell activation 
in vitro and in antigen-driven inflammation in vivo.
Since its discovery,30 RNAi technology has rapidly emerged, 
not only as a new strategy for target validation and functional 
genomics, but also as a promising therapeutic approach for 
otherwise “undruggable” targets (i.e., molecules without ligand 
binding domains or those that have structural homology with 
other family members or critical proteins in the cell).31 However, 
applied to the lymphoid lineage, there are still several technical 
limitations namely siRNA delivery, RNAi pathway functionality 
and off-target effects.21,23,32–34
To tackle these challenges, in this study we have used 
ACCELL siRNA sequences, that include chemical modifica-
tions to improve stability and target specificity, avoid off-target 
effects and allow vector-free delivery efficiency into difficult-to 
transfect cells. We have achieved an almost absolute siRNA 
delivery in human and murine primary T lymphocytes. Fur-
thermore, specific and stable target knockdown (Jak1 and 
Jak3) was observed at the RNA and protein level. Interest-
ingly, Jak1 mRNA and protein content slightly increased in 
response to Jak3 knockdown, likely due to the loss of nega-































































































































Figure 5 Murine lymphocytes small interference rnA (sirnA) transfection setup and endogenous target silencing. (a) BALB/c 
Th1 cells were incubated in the absence (empty histogram) or presence of 1 µmol/l Scrambled ACCELL siRNA fluorescently labeled with 
CyTM3 (red histogram) for 3 days. On the third day, fluorescence incorporation was assessed by flow cytometry. A representative histo-
gram of four independent experiments is shown. (b) Cytoplasmatic localization of CyTM3-labeled scrambled siRNA sequences (red) was 
confirmed by confocal microscopy in the same cells. FITC-CD3 mAb (green) was used as a T cell membrane marker. Nuclei were labeled 
with DRAQ5 (blue). A representative view of three independent experiments is shown. For silencing efficiency experiments, cells were 
left unstimulated (Th1-), or stimulated with Th1 cytokines during incubations in absence (Mock) or presence of 1 µmol/l Scrambled (Scr), 
mJak3 ormJak1 siRNA sequences. On the third day (c) jak1 and (d) jak3 mRNA levels were assessed by quantitative reverse transcription-
PCR (RT-PCR). gusb was used as housekeeping gene. Data are expressed as mean ± SEM relative to nonstimulated cells (Th1-); n = 5; 
*P < 0.05 versus Scr; n.s.; nonsignificative; one-tailed Student’s t-test.
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rather than Jak3.35,36 However, the consequences of the little 
Jak1 upregulation observed could be diverse as long as 
Jak1 is associated with cytokine receptors other than γc in 
which Jak3 is not associated: on the one hand Jak1 asso-
ciates with IFNα and IFNγ receptors. These cytokines are 
involved in innate immune response; therefore maintaining 
a Jak1 residual activity may be positive in order to be able to 
respond against pathogens. This might be crucial to prevent 
the susceptible to pathogens seen in clinical trials testing 
pan-Jak inhibitors.11,12,18 On the other, Jak1 also associates 
with IL-6 cytokine receptor. IL-6 is one of the most abundant 
proinflammatory cytokines found in both the joint and blood 
of patients with active rheumatoid arthritis;37 but whether this 
would translate on an exacerbated IL-6 signal transduction is 
not clear. The effect of an increase of Jak1 in this scenario is 
uncertain and would need to be further evaluated in a rheu-
matoid arthritis model.
Importantly, no signs of toxicity (cell death or apoptosis) 
intrinsic to the transfection method or siRNA sequences was 
observed at any experimental time, in contrast to some recent 
studies that have reported activation of the innate immune 
system due to so called immunostimulatory RNA.34 The 
secretion of markers like IFNγ and IL-6 secretion,38 as well 
as 2′-5′ oligoadenylate synthetase 2 (Oas2) and suppressor 
of cytokine signaling 1 (SOCS1) mRNA levels33,39 was unal-
tered after siRNA treatments (data not shown), dismissing 
both sequence-dependent and independent immunostimula-
tory RNA -trigger off-target effects.
In summary, these results are a significant step forward 
to efficient and nontoxic siRNA transfection experiments in 
lymphoid cells, opening new avenues into target validation 
studies in leukocyte-implicated diseases. Current pharmaco-
logical approaches for autoimmune disorders are focusing 
on small molecule inhibitors for molecular targets involved 
in either T cell or B cell activation,40 including Jak3, that has 
positioned itself as one of the most desirable targets.2,4,5,7,8
The clinical efficacy of Jak inhibition has been recently 
proven in clinical trials for rheumatoid arthritis and kidney 
allograft rejection.10–12 However, these studies revealed sec-
ondary side-effects (anemia, neutropenia, dyslipidemia) most 
likely due topan-Jak inhibition. Although the selectivity pattern 
of Jak inhibitors in vitro has been recently improved without 
harming the in vivo activity in mouse models,9,19 these data 
should be carefully interpreted because (i) the specificity pro-
file can vary considerably depending on the assay format used 
to gauge selectivity, and (ii) the interpretation of the in vivo effi-










































































































































































































Figure 6 Specific Jak3 knockdown alleviates inflammation in 
vivo. OVA-TCRtg stimulated Th1 cells were Mock, Scrambled small 
interference RNA (siRNA), mJak3 siRNA or mJak3+mJak1 siRNA 
transfected at 1 µmol/l each as stated in Materials and Methods 
section. After 72 hours, 5 × 106 cells were adoptively transferred 
into naive syngeneic recipient mice. Twenty four hours after adop-
tive cell transfer, mice were challenged by s.c. injection of 5 µg 
OVA323–339/incomplete Freund’s adjuvant (IFA) emulsion in the right 
footpad. As a control, nonadoptively transferred naive mice were 
used (Ct). (a) Plasmatic interferon-γ (IFNγ) levels 24 hours after 
OVA323–339 challenge were determined by enzyme-linked immuno-
sorbent assay (ELISA). Data are mean ± SEM; n = 6; *P < 0.05 
versus Scr. (b) Footpad swelling was measured 24 hours after 
challenge. Results were defined as % inflammation relative to the 
background in 0% control (Ct) and the 100% control (Mock), re-
spectively. Data are mean ± SEM of 12 animals analyzed in two 
independent experiments. *P < 0.05; #P < 0.01 versus Scr. (c) Cell 
migration in the delayed type hypersensibility (DTH) test site was 
evaluated in hematoxylin-eosin stained sections from Mock (pan-
els i), Scr (panel ii), and Jak3 groups (panels iii and iv). Repre-
sentative images of five samples analyzed per group are shown. 
Arrows point to cellular infiltrate indicative of inflammation. Size 
bars represent 200 µm. (d) Histological score for inflamed footpads 
was awarded as stated in Material and Methods. n = 4–5; *P < 
0.05, #P < 0.01, one tailed Student’s t-test versus Scr. Finally, 24 
hours after in vivo OVA323–339 challenge, draining lymph node cells 
were collected and rechallenged in vitro with 10 µg/ml OVA323–339 
further 48 hours. At this point, proliferation and IFNγ secretion were 
evaluated. (e) Proliferation response was estimated as relative cell 
viability versus nonchallenged cells (0 µg/ml OVA323–339) in each 
group. (f) Supernatant IFNγ was measured by enzyme-linked im-
munosorbent assay (ELISA). Data are mean ± SEM of 4–7 mea-
surements from two independent experiments. *P < 0.05 versus 
Scr. TCR, T cell receptor.
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by their different kinetic properties. In this scenario, it remains 
unanswered whether an acute Jak3-specific inhibition is suf-
ficient to disrupt γc cytokine signaling and, if so, could it result 
in efficacious amelioration of immune-related disorders?
In our in vitro experiments we have found that a single 
(either Jak1 or Jak3) intervention was enough to disrupt IL-2 
signal transduction (i.e., Stat 5a/b phosphorylation) and down-
stream effects (i.e., target genes transcription, IFNγ secre-
tion and proliferation) in primary T lymphocytes. There are 
several implications on these results: (i) Jaks have obligatory 
and nonredundant roles in cytokine-mediated responses, as 
stated in knockout strains.4,17,26 (ii) Since Jak3 pair Jak1 in all 
γc receptor-mediated signaling pathways, Jak3 inhibition may 
interfere not only with IL-2 but also with all γc cytokine signal-
ing, some of which play an important role in the pathogen-
esis of autoimmune diseases.37 (iii) Jak1 inhibition would also 
interfere with other cytokine-mediated pathways, such as IL-6 
family (whose relevance in autoimmunity has been demon-
strated37) and the type II receptors such as the IFNs and the 
IL-10 family.1–3 This represents a double-edged sword: while 
inhibiting Jak family more broadly might potentially provide 
stronger efficacy since different cytokine signaling pathways 
will be blocked, the adverse effects of a systemic multi-cy-
tokine inhibition should be carefully evaluated.
Furthermore, we have found evidence suggesting that, in the 
IL-2 signaling cascade, there is a hierarchy led by Jak3. Firstly, 
Jak3 knockdown abrogates Jak1 phosphorylation in response 
to IL-2 while residual Jak3 is hyperactivated (probably due to 
signaling cut-off), but not vice-versa. These results advocate 
an upstream function of Jak3 in a trans-phosphorylation phe-
nomenon triggered by IL-2, and suggest that Jak1 may be a 
substrate of Jak3. These observations agree with those made 
by others in different cell lines or heterologous systems.41,42 
Secondly, in spite of equivalent Jak1 and Jak3 knockdown effi-
ciency, Jak3 abrogation resulted in a small but consistent ten-
dency toward a stronger phenotype in specific readouts (less 
Stat5a/b phosphorylation and greater cell viability loss). This 
could be suggestive of Jak3 supremacy in IL-2 signal trans-
duction in T lymphocytes. This fact has also been described by 
others in megacarioblastic43 and fibroblast44 cell lines, and in 
other γc cytokines like IL-4.45 Taken together, evidence shown 
here reinforce the importance of cross-talk among receptor-
associated Jak kinases and discards a functional redundancy 
in this system. Furthermore, our results suggest a first-step 
and dominant role of Jak3 in common-γc receptors signal 
transduction and discard the need of a dual Jak1–Jak3 inter-
vention to fully disrupt γc cytokine signaling.
Relationship between Jak3 and T cell receptor (TCR) is 
controversial. Some have described intact TCR signaling 
in Jak3–/– T cells,26 whereas others have found impairment 
in CD3 mAb-induced TCR activation in Jak3–/– T cells and 
direct association of Jak3 with CD3ζ subunit.25 Furthermore, 
uncoupled early TCR-triggered signalling from essential 
downstream events after Jak3 pharmacological inhibition has 
been described.24 However, these studies were made using 
either transgenic knockout mice strains, that could reflect an 
adaptive response,46 or pharmacological inhibitors which are 
neither specific nor potent and should be carefully interpreted. 
Results here presented provide a direct link between Jaks 
and TCR: we have found that both Jak3 and Jak1 knockdown 
compromises CD3-CD28 mAb-induced phosphorylation 
of TCR CD3ε subunit, as well as the downstream mediator 
CREB. Cell clustering and proliferation, phenotypic hallmarks 
of TCR activation, were concurrently affected. These results 
support a plausible role of Jak kinases in the TCR-pathway 
which would be acting as cross-talking molecules for T cell 
activation at different points: antigen recognition (signal I and 
II) and cell growth signals transduction (signal III).
However, inflammation is a complex process mediated 
by multiple cytokines where a number of cell types interact. 
Therefore, we next aimed at assessing to what extent-spe-
cific Jak3 knockdown in effector T cells would be sufficient 
to prevent an inflammatory process in vivo. Th1-mediated 
DTH allowed us to recreate a complex inflammatory scenario 
mediated by endogenous counterparts while modulating the 
expression of Jak proteins. We observed a significant allevia-
tion of the inflammatory process was obtained in response 
to approximately 50% Jak3 knockdown in our model. In cor-
relation to in vitro observations, Jak1 cosilencing did not 
cooperate to obtain a greater anti-inflammatory effect. Very 
noteworthy our in vivo results sustained that selective Jak3 
inhibition could provide immunosuppressive effect in inflam-
matory disorders avoiding potential secondary effects due to 
pan-Jak inhibition outside immune system.
Jak3 silencing could impair the inflammatory process by dif-
ferent mechanisms: (i) T cell activation. As seen in our in vitro 
restimulation experiments, T cells could remain refractory to 
antigen-mediated activation in vivo in absence of Jak3, due 
to either disruption of γc cytokine signaling, TCR pathway or 
both. (ii) Antigen priming: besides T cells, DC from the syn-
ovial tissue of rheumatoid arthritis patients have been found 
to express Jak38 although its functional role is unknown. Tak-
ing into account that Th1 cultures started up from a mixture of 
splenocytes and lymph nodes cell suspension, where there 
are many DC, we cannot rule out the possibility that Jak3 
knockdown efficiency in vivo might be, at least in part, due 
to impaired DC triggering. (iii) Th1 differentiation: Jak3 has 
been described to play a role in Th1 differentiation by means 
of epigenetic modifications.47
To sum up, in this study we have demonstrated that Jak3-
specific suppression in lymphocytes is enough to damper 
IL-2 and CD3-CD28-mediated T cell activation in vitro and 
Th1 antigen-driven inflammation in vivo. The data here pre-
sented strongly supports the hypothesis that specific Jak3 
inhibition could be effective to treat autoimmune disorders 
where inflammatory pathways such as IL-2 signaling, TCR 
activation, antigen presentation and a Th1 cellular response 
has been found to be major insights.7,8 Such therapeutic strat-
egy would balance potential adverse effects versus efficacy.
A remaining question to answer, however, is the feasibil-
ity to synthesize a Jak3-selective small molecule inhibi-
tor, as many kinase inhibitors work by interaction with the 
ATP-binding cleft.13 Since the generation of selective kinase 
inhibitors versus other kinase families seems to be feasible, 
there are still many challenges in synthesizing a specific Jak3 
antagonist versus other family members, although significant 
improvements are being made.19,48 As long as T cell-selec-
tive systemic siRNA delivery has recently been described,49 
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a plausible alternative would be the development of a Jak3 
siRNA-based immunosuppressive therapy.
MAterIALS And MethodS
siRNA sequences. ACCELL siRNA were  purchased from 
Thermo Scientific Dharmacon (Lafayette, CO). Selected 
mRNA target sequences tested were: human Jak1: 
5′ccagaauguuuaaugcaau3′ and 5′ggaugagguucuauuucac3′; 
human Jak3: 5′ccauggugcaggaauuugu3′ and 5′ggguccuucacc 
aagauuu3′; mouse Jak1: 5′gcuuugugcugaaacgaug3′; mouse 
Jak3: 5′uccuugacuuacacguuuu3′. As negative controls, siR-
NA-free treatment (Mock) and nontargeting siRNA sequence 
(Scrambled; Scr) were used.
Human primary T lymphocytes isolation, culture, and 
 transfection. Peripheral blood T lymphocytes from healthy vol-
unteers were isolated using Ficoll (Biochrom, Berlin,  Germany) 
density gradient centrifugation. Thereafter, T cells were further 
isolated with the MACS pan T cell Isolation kit by negative 
selection in MACS LD depletion magnetic columns (Milteny-
iBiotec, Bergisch Gladbach, Germany). The T-cell isolation 
procedure yielded >92% CD3+ cells. T lymphocytes were cul-
tured at a density of 1 × 106/ml for 3 days in complete RPMI 
(RPMI 1640, 2 mmol/l glutamine, 10 mmol/l Na/Pyruvate, 100 
U Penicillin, 100 µg/ml Streptomycin and 10% inactivated fetal 
bovine serum, all from Gibco, Paisley, UK) supplemented with 
10 µg/ml PHA (Roche, Indianapolis, IN). Afterwards, cells were 
washed and further cultured in complete RPMI supplemented 
with 50 ng/ml human recombinant IL-2 (BD Bioscience, San 
Diego, CA) during all experimental processes.
Transfections were conducted on the fourth day of IL-2 incu-
bation in ACCELL medium w/o fetal bovine serum at a cell 
density 4 × 106 cells/ml with 1 µmol/l ACCELL siRNA for 3 days 
to allow passive transfection. Afterwards, cells were either col-
lected, or diluted to 1 × 106 cells/ml in complete RPMI.
Confocal microscopy. Cells were fixed in 4% paraformal-
dehyde on d3 after transfection. The T cell membrane was 
highlighted using anti-FITC or Cy3TM labeled CD3mAb (BD 
Pharmingen, San Diego, CA). Nuclei were labeled with 5 
µmol/l DRAQ5 (Biostatus, Leicestershire, UK). Cells were pel-
leted using a cytospin and mounted in Mowiol-0.1% DABCO 
(Sigma-Aldrich, St Louis, MO). Fluorescence was detected 
using a spectral confocal microscope (Leica TCS-SL) at the 
Research Support Services from the Biology Unit of Bell-
vitge, University of Barcelona (Barcelona, Spain).
RNA extraction and quantitative reverse transcription-PCR. 
Total RNA was extracted using RNAeasy mini kit (Qiagen, 
Mannheim, Germany) or Tryzol reagent (Invitrogen, Carlsbad, 
CA). RNA quality was assessed using a Bioanalyzer 2100 
system at the Transcriptomic Platform from Research Support 
Services, Scientific Parc from Barcelona (PCB) (Barcelona, 
Spain). To obtain cDNA 50–200 ng of RNA was reverse tran-
scribed using random hexamers plus either the reverse tran-
scription reagents kit (Applied Biosystems, Branchburg, NJ) or 
SuperScriptVILO (Invitrogen) for human and mouse samples, 
respectively. Expression levels of mRNA for selected genes 
were quantified using TaqMan probes and Gene Expression 
Master Mix in a 7500HT Real Time-PCR system (all from 
Applied Biosystems). Gene expression was normalized with 
β-glucoronidase (Gusb) and 18S as a housekeeping gene with 
equivalent results. Data analysis is based on the ∆∆Ct method.
Western blot. Cells were lysed in RIPA buffer containing pro-
tease and phosphatase inhibitor cocktail (Roche, Mannheim, 
Germany) and 1 mmol/l phenylmethylsulfonyl fluoride. Protein 
concentration was measured by BCA (Pierce, Rockford, IL). 
Equivalent amounts of proteins from whole cell lysates (20–50 
µg) were resolved by electrophoresis in 7.5% sodium dodecyl 
sulfate-polyacrylamide gels (SDS-PAGE). Gels were electro-
transferred to PVDF membranes (Millipore, Billerica, MA). 
Membranes were then incubated with primary antibody fol-
lowed by horseradish peroxidase-conjugated secondary anti-
body. Jak1 primary antibody (Chemicon, Temecula, CA) was 
used at 1/500 dilution, while human Jak3 (Cell Signaling, Dan-
vers, MA) and mouse Jak3 (B12) (Santa Cruz Biotechnology, 
Heidelberg, Germany) specific antibodies were diluted 1/1,000 
and 1/200, respectively. Phosphorylation of the kinase domain 
(JH1) was detected using the phospho-specific antibody 
P-JAK1 (Tyr1022–1023) (Santa Cruz Biotechnology) at 1/200 dilu-
tion, which recognizes P-Tyr1022/1023 and P-Tyr980–981 from Jak1 
and Jak3 respectively. Blots were normalized using γ-tubulin 
antibody, diluted 1/10,000 (Sigma-Aldrich). Corresponding 
secondary antibodies were diluted 1/20,000. The membranes 
were developed with enhanced chemiluminescence (SuperSig-
nal West Dura; Thermo Scientific, Rockford, IL) and visualized 
in a Molecular Imager ChemiDoc XRS System from Bio-Rad 
(Barcelona, Spain). Densitometric scanning of immunoblots 
was performed using the Quantity One analysis software.
Cell viability. Cell viability was indirectly measured using the 
CellGlo viability assay (Promega, Madison, WI) following 
manufacturer’s guidelines.
Flow cytometry analysis. Cytometric analysis was performed 
on fresh cells using a FACS calibur cytometer and CellQuest 
software (BD Bioscience, Bedford, MA).
Luminex. Stat5a/b and TCR activation were investigated by 
means of xMAP technology in a LIFECODES Life Match Flu-
oro Analyzer apparatus (Tepnel, Stamford, TP) equipped with 
Luminex 100 IS 2.3 software. On the third day after transfec-
tion 12.5 µg of cell lysates were obtained for analysis following 
supplier guidelines. Steady-state Stat5a/b phosphorylation 
levels were analyzed using MILLIPLEX Phospho Stat5a/b 
(Tyr694/699) MAPMates (Millipore). TCR signaling pathway 
(CD3 and CREB phosphorylation levels) was analyzed using 
a Beadlyte 7-plex human T receptor signaling kit (Millipore) 
after 10-minute stimulation with 1 µg/ml CD3 and 0.5 µg/ml 
CD28 mAb (BD Biosciences). Data are expressed as relative 
phosphorylation levels versus nonstimulated control cells.
Mice. Female BALB/c mice were purchased from Harlan 
Interfauna Ibérica SI (Barcelona, Spain) and female DO11.10 
mice from Charles River Laboratories (Barcelona, Spain). All 
mice were used between seven to fourteen weeks-old and 
maintained in a constant 12 hours light-dark cycle, fed a 
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standard rodent chow and water ad libitum. All animal proto-
cols were approved by the Animal Experimentation Commit-
tee from the Generalitat de Catalunya.
Generation and transfection of murine Th1 cells. Single cell 
suspensions from mouse splenocytes and mesenteric lymph 
nodes were prepared by 100-µm mesh filtration followed by 
erythrocytes lysis with AKC buffer. Cell concentration was 
adjusted to 2 × 106 cells/ml and lymph node cells were cocul-
tured with splenocytes at a 1:2.5 ratio. Cells were grown in 
VLE-RPMI 1640 medium with stable glutamine (Biochrom) 
containing 10% heat-inactivated fetal bovine serum (Gibco), 
50 µmol/l β-mercaptoethanol (Sigma-Aldrich), 100 U/ml peni-
cillin and 100 µg/ml streptomycin sulfate (Gibco). To induce 
Th1 differentiation, cells were incubated with a Th1 cytokine 
cocktail consisting of recombinant mouse IFNγ (20 ng/ml), 
IL-12 (10 ng/ml), IL-2 (5 ng/ml), all of them purchased from 
PeproTech EC (London, UK). After 2 days, cells were incu-
bated with 1 µmol/l siRNA in serum depleted (2%) complete 
VLE-RPMI 1640 plus Th1 cytokine cocktail. Cells were left in 
cultured for three more days to allow passive transfection prior 
to either knockdown assessment or adoptive cell transfer.
Th1-mediated DTH in vivo model. T cells from DO11.10 
mice express a transgenic TCR recognizing OVA323–339 pep-
tide.50 OVA323–339-specific Th1 effector cells were generated 
ex vivo by antigen-specific activation of Th1 culture with 
2 µg/ml OVA323–339 peptide (GenScript, Piscataway, NJ). After 
5 days in culture, these cells were used for adoptive cell trans-
fer. 5 × 106 activated DO11.10 Th1 cells (OVA-TCRtg Th1) 
were intravenously injected into naive BALB/c mice. After 
24 hours, a DTH response was induced by subcutaneous 
injection of 5 µg OVA323–339 peptide emulsified in incomplete 
Freund’s adjuvant (Sigma-Aldrich) into the right footpad. As 
a control, the left footpad was injected with an equivalent vol-
ume of phosphate-buffered saline-incomplete Freund’s adju-
vant. This treatment induces a strong DTH reaction within 
the footpad containing the OVA323–339 peptide, with a peak 
response 24 hours after the challenge.28 At this time point, 
the inflammatory reaction was measured using a Dial Thick-
ness Gauge (0.01–10 mm) (Peacock, Ozaki MFG, Japan). 
Footpad swelling was calculated by subtracting footpad thick-
ness measured before, and 24 hours after challenge from 
each individual animal. The degree of footpad swelling was 
calculated as: percentage increase = [(right footpad thick-
ness after antigen challenge/uninjected left footpad thickness 
after antigen challenge) – 1] × 100.
In vitro antigen-specific restimulation of Th1 cells. To analyze 
antigen-specific cellular response, popliteal lymph nodes 
were isolated 24 hours after in vivo OVA323–339 challenge and 
4 × 105 cells cultured in complete VLE-RPMI medium in pres-
ence or absence of 10 µg OVA323–339 for 48 hours. Cellular via-
bility and IFNγ secretion in the supernatant was assessed.
Histology. Histological evaluation of inflamed footpad tissue 
was performed 24 hours after DTH induction. For hematoxy-
lin and eosin staining formalin-fixed samples were decalci-
fied, paraffin-embedded and 4-µm sections were obtained. 
Evaluation was performed by microscopic analysis by an 
experienced pathologist in a blind fashion (ANAPATH, Gran-
ada, Spain). For overall infiltration and tissue damage a 0 to 
4 score was used (footpad score) as follows: 0, no infiltrates, 
no edema; 1, scarce infiltrates within subcutaneous tissue, 
little edema; 2, moderate edema, mild infiltrates within sub-
cutaneous fatty tissue; 3, moderate edema, mild infiltrates in 
skeletal muscle; and 4, abscess formation, with severe infil-
trates in skeletal muscle.
Statistical analysis. Results are expressed as the mean ± 
SEM. Statistical analysis was performed, unless otherwise 
stated, by two tailed Student t-test on two group comparison 
and one-way ANOVA for multiple comparisons. Data were 
considered statistically significant when P < 0.05.
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